[go: up one dir, main page]

US20080103438A1 - Method For Reducing Or Eliminating Residue In A Glass Container And A Glass Container Made In Accordance Therewith - Google Patents

Method For Reducing Or Eliminating Residue In A Glass Container And A Glass Container Made In Accordance Therewith Download PDF

Info

Publication number
US20080103438A1
US20080103438A1 US11/664,236 US66423605A US2008103438A1 US 20080103438 A1 US20080103438 A1 US 20080103438A1 US 66423605 A US66423605 A US 66423605A US 2008103438 A1 US2008103438 A1 US 2008103438A1
Authority
US
United States
Prior art keywords
glass blank
glass
pin
channel
forming
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/664,236
Other languages
English (en)
Inventor
Alfred W. Prais
Bruno Cocheteux
Arturo Cortes
Patrice Delabie
Edouard Wales
Richard Dale Luedtke
Randy Schaecher
Daniel Vulliet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Becton Dickinson and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36072208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080103438(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US11/664,236 priority Critical patent/US20080103438A1/en
Publication of US20080103438A1 publication Critical patent/US20080103438A1/en
Assigned to BECTON, DICKINSON AND COMPANY reassignment BECTON, DICKINSON AND COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CORTES, ARTURO, DELABIE, PATRICE, VULLIET, DANIEL, LUEDTKE, RICHARD DALE, PRAIS, ALFRED W., SCHAECHER, RANDY
Assigned to BECTON, DICKINSON AND COMPANY reassignment BECTON, DICKINSON AND COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WALES, EDOUARD
Assigned to BECTON, DICKINSON AND COMPANY reassignment BECTON, DICKINSON AND COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WALES, EDOUARD
Assigned to BECTON, DICKINSON AND COMPANY reassignment BECTON, DICKINSON AND COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COCHETEUX, BRUNO
Priority to US17/326,022 priority patent/US20210269349A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03B—MANUFACTURE, SHAPING, OR SUPPLEMENTARY PROCESSES
    • C03B23/00—Re-forming shaped glass
    • C03B23/04—Re-forming tubes or rods
    • C03B23/09—Reshaping the ends, e.g. as grooves, threads or mouths
    • C03B23/092—Reshaping the ends, e.g. as grooves, threads or mouths by pressing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/3129—Syringe barrels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/3129—Syringe barrels
    • A61M5/3134—Syringe barrels characterised by constructional features of the distal end, i.e. end closest to the tip of the needle cannula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/34—Constructions for connecting the needle, e.g. to syringe nozzle or needle hub

Definitions

  • This invention relates to a method for reducing tungsten and derivatives thereof in a glass container and to a glass container with reduced tungsten and derivatives thereof.
  • Tungsten and derivatives thereof have been commonly used in glass forming techniques.
  • tungsten-containing pins have been used in forming shaped apertures or channels in glass structures.
  • the term “tungsten-containing” means tungsten, tungsten plus one or more other materials, or one or more other materials plus tungsten, in any combination and percentage.
  • Tungsten has a high fusion temperature relative to glass and is well suited for glass manufacturing.
  • a tungsten-containing pin is used to form an aperture or channel in a glass container, with the glass being thermally and/or mechanically manipulated about the pin and into conforming engagement therewith.
  • An iterative process can be used where a plurality of pins are used sequentially to gradually form the aperture or channel in a sequence of manipulations to the glass. With removal of the final pin, a finished aperture or channel is left in the glass structure.
  • This technique has been commonly used in the formation of glass medical containers, including glass syringe barrels, glass vials, and glass drug cartridge bodies.
  • Each of the glass medical containers includes a reservoir for containing a drug, and a channel in communication with the reservoir to provide a means of accessing or removing the drug from the reservoir, typically via a cannula or similar liquid communication means.
  • tungsten-containing pins undesirably leave a tungsten-containing residue on the formed glass structures, particularly, portions that had been in contact with the pins, for example, the aperture or channel.
  • the tungsten-containing residue may have detrimental effects on any substance contained or stored within the glass medical container.
  • tungsten or derivatives thereof may be deposited as particulate matter on an inner surface of the aperture or channel, and such particulate matter may be visible in the contained substance.
  • Certain medical procedures require a medical practitioner to view the procedure under magnification, including the administration of a drug from a glass medical container. The presence of such particulate matter may be dangerous to the patient and may also be disconcerting to the medical practitioner.
  • drugs containing proteins may be adversely affected by exposure to the tungsten or derivatives thereof. Certain proteins are prone to clump or aggregate about tungsten or derivatives thereof. This clumping or aggregation may lead to a loss in efficacy or other undesirable effects of the drug. In addition, in certain situations, the clumping or aggregation may be so extreme that solid fragments may be seen by the naked eye and be disconcerting to a potential user.
  • washing glass medical containers is known in the prior art. Such washing techniques have been known to reduce or remove tungsten-containing residue. However, washing techniques have inherent limitations and cannot reliably and repeatedly remove all or substantially all tungsten and derivatives thereof from a glass medical container.
  • a method for preparing a glass medical container including the steps of providing a glass blank and forming a channel through a part of the glass blank, the channel being substantially free of tungsten or derivatives thereof.
  • a glass medical container is provided including a glass body having a channel extending through a part of the glass body, the channel being substantially free of tungsten or derivatives thereof. With the subject invention, tungsten or derivatives thereof can be generally or altogether completely avoided in glass medical containers.
  • a “drug” is an illustrative and non-limiting term and refers to any substance to be injected into a patient for any purpose; “tungsten or derivatives thereof” shall mean tungsten or any substance containing tungsten, including, but not limited to, tungsten salts and tungsten-containing alloys; and, “substantially free” shall mean a level of tungsten or derivatives thereof low enough to not detrimentally alter or affect a drug.
  • substantially free may mean tungsten or derivatives thereof at a level that the tungsten or derivatives thereof is not visible, does not detrimentally alter the efficacy or otherwise adversely effect the drug, and/or does not detrimentally promote unacceptable levels of clumping or aggregation of proteins contained in the drug.
  • FIG. 1 is a plan view of an exemplary glass medical container in accordance with the subject invention
  • FIG. 2 is a schematic showing formation of a channel in a glass medical container.
  • FIG. 3 is a partial cross-sectional view of an alternative channel shape formed in a glass medical container.
  • a method for substantially reducing or altogether eliminating tungsten or derivatives thereof from a glass container without the need for additional annealing, sterilization or washing steps after the container has been completely formed.
  • the method is particularly well-suited for use in forming glass medical containers.
  • an exemplary glass medical container 10 is shown and described which is in the form of a glass syringe barrel.
  • the glass medical container 10 can be any glass body used for containing or storing a liquid and/or dry substance, including, but not limited to glass syringe barrels, glass vials, and glass drug cartridge bodies.
  • the glass medical container 10 defines a reservoir 12 and has a hub 8 with a channel 14 defined therethrough and in communication with the reservoir 12 .
  • the glass medical container 10 is preferably a unitary glass body.
  • the channel 14 forms an aperture 16 at a distal end of the glass medical container 10 .
  • the channel 14 via the aperture 16 , provides access to the reservoir 12 and any drug which may be contained therein.
  • the channel 14 is formed through the hub 8 .
  • the reservoir 12 as formed in the glass medical container 10 , may partly define a volume for containing a drug.
  • a piston, plunger, septum, tip cap, stopper, and so forth, may be used in connection with the glass medical container 10 to form a closed volume for containing a drug within the reservoir 12 .
  • a process in accordance with the subject invention is depicted for forming the channel 14 .
  • a pin 20 is provided to form and extend into and possibly through an opening 22 defined in a glass blank 24 .
  • the glass blank 24 is a partially formed version of the glass medical container 10 .
  • a glass blank 24 may comprise a generally cylindrical part having a substantially constant outer diameter, or it may be a partially or completely formed part having a portion through which the channel 14 is formed and defined. Thermal and mechanical manipulations are performed on and to the glass blank 24 to form the final glass medical container 10 as is known in the art.
  • the opening 22 is in communication with reservoir 26 which ultimately, after full formation, results in the reservoir 12 .
  • the channel 14 portions of the glass blank 24 about the opening 22 are manipulated, either in one process or in iterations, to force the portions of the glass blank 24 into conforming engagement with the pin 20 .
  • the manipulations may include mechanical manipulations (e.g., rolling or other shape forming processes) and/or thermal manipulations (e.g., heating glass to a malleable state).
  • the channel 14 is generally formed with a cross-sectional shape corresponding to the exterior surface of the pin 20 .
  • the pin 20 is shown with a constant cross-section along its length.
  • the channel 14 also has a constant cross-section along its length.
  • Alternative configurations for the channel 14 are possible.
  • the channel 14 is shown with varying cross-sections along its length. This configuration is preferred for staked needle configuration glass syringe barrels, while the constant cross-sectional configuration of FIG. 1 is preferred for Luer tip mounted needle configurations.
  • a first portion 21 of the channel 14 defines a substantially constant diameter D 1
  • a second portion 23 of the channel 14 located closer to the reservoir 12 , defines a substantially constant diameter D 2 .
  • the diameter D 1 is larger than the diameter D 2 with a step 25 being formed therebetween.
  • the step 25 acts as a stop against an insertion of a needle during assembly.
  • the needle is glued or otherwise secured within the first portion 21 and in communication with the second portion 23 .
  • the channel 14 can take on various configurations (e.g., more than two diameter changes, tapering, etc.), and, as is readily recognized, the pin 20 is shaped externally to achieve the desired configuration of the channel 14 .
  • the pins 20 having different diameters may be used to form a channel 14 as shown in FIG. 3 , e.g., sequentially.
  • the channel 14 may have a configuration as in FIG. 1 with a continuous diameter of about 1.0 mm; or, the channel 14 may a configuration as in FIG. 3 with a diameter D 1 of about 0.6 mm, and a diameter D 2 in the range of 0.2 to 0.4 mm. Also, the channel 14 , as is common with glass syringe barrels, defines a diameter smaller than the internal diameter defined by the reservoir 12 . With a vial configuration or a drug cartridge body configuration, the channel 14 may have a diameter generally equal to the internal diameter of the reservoir 12 , or even greater than the internal diameter of the reservoir 12 .
  • the pin 20 be formed of a material that will not oxidize during the glass forming process described above. Generally, all materials can be oxidized, although special circumstances may be required for oxidation. With the glass forming process discussed above in connection with FIG. 2 , the pin 20 may be thermally manipulated by exposure during thermal manipulation of the glass blank 24 to temperatures in the range of 600° C.-900° C., and may be subjected to elevated pressures generated by shape-forming tools during mechanical manipulation of the glass blank 24 . Under these conditions, tungsten oxidizes.
  • the pin 20 is typically used in large scale, repetitious manufacturing and subjected to fast thermal cycles of heat application and removal, resulting in fatigue to the surface of the pin 20 and consequently, to the pin 20 .
  • Surface fatigue leads to weakening of the structure of the pin 20 and mechanical failure with fragments (typically microscopic) thereof breaking off during use of the pin 20 in the glass forming process and, consequently, to deposition of tungsten or derivatives thereof on and within the channel 14 .
  • the pin 20 be formed of a material which does not oxidize when subjected to a glass forming process which is may be typically conducted under temperatures in the range of 600° C.-900° C. and under elevated pressure caused by shape-forming tools. These conditions hereinafter shall be referred to as “glass forming process conditions.” It will be obvious to persons skilled in the art that other conditions and parameters may be present during the process of forming a glass blank into a glass medical container.
  • materials that will not oxidize under the glass forming process conditions, and useable for the pin 20 in accordance with the present invention include, but are not limited to, the following: metals or alloys containing platinum or platinum group metals; metals or alloys containing nickel; ceramics; silicides; and combinations thereof. It is preferred that the pin 20 be formed of a platinum/rhodium alloy with 80%-90% platinum and 20%-10% rhodium. With the pin 20 being formed of one of the aforementioned materials, or other material(s) that will not oxidize under the glass forming process conditions, deposition of tungsten or derivatives thereof on the glass medical container 10 due to the oxidation process can be avoided. As a result, the channel 14 can be formed substantially free of tungsten or derivatives thereof. It is also preferred that the pin 20 have a melting temperature above the melting temperature of the associated glass being formed into the glass medical container 10 .
  • An alloy containing tungsten may be used to form the pin 20 where the tungsten-containing alloy does not oxidize under the glass forming process conditions.
  • the pin 20 may be formed of with a tungsten carbide which does not oxidize under the glass forming process conditions.
  • the present invention may also control the environment in which the pin 20 is forming the channel 14 by introducing a controlling gas in the area of the pin 20 and channel 14 .
  • a controlling gas for example, the introduction of an inert gas such as nitrogen gas, by way of non-limiting example, in and around the area in which the pin 20 is used to reduce the oxygen content in that area can reduce oxidation of the pin 20 .
  • the formation of the channel 14 may require various sequential forming steps including multiple pins 20 , such as pins 20 of constant or varying diameters.
  • the channel 14 may be iteratively formed smaller over a sequence of forming stages with increasingly smaller diameter pins 20 being used. In each forming stage, the channel 14 is brought into conforming engagement with the associated pin 20 , until a final forming stage is reached. All of the pins 20 used in the various stages in the formation of the channel 14 may be formed of the preferred materials described above. Alternatively, it has been found that certain forming stages may cause greater deposition of tungsten or derivatives thereof than other forming stages.
  • the pins 20 be formed of materials which do not oxidize under the glass forming process conditions and which do not include tungsten.
  • the less critical forming stages may use pins formed of any material, including tungsten.
  • the last forming step utilize the pin 20 being formed of materials which do not oxidize under the glass forming process conditions and which do not include tungsten.
  • the preceding forming stages may be formed of any material suitable for pin formation.
  • the less critical forming stages may not expose the pin 20 to the same amounts of thermal and/or mechanical manipulation because the channel 14 is only roughly formed and thus may not contact the pin 20 to the same extent as may occur during the final forming stage(s).
  • the channel 14 can advantageously be formed substantially free of tungsten or derivatives thereof. Using the following procedure for measuring concentration, it is preferred that the channel 14 have tungsten or derivatives thereof in an amount of 12 parts per billion or less. With the preferred process, not only is oxidation of the pin 20 avoided, but the pin 20 may be formed to not deposit tungsten or derivates thereof even under mechanical failure. This preferred process may produce glass medical containers which have undetectable levels of tungsten or derivatives thereof. These concentration levels are obtainable with the subject invention on large scale, industrial processes within highly acceptable tolerance levels. Prior art washing techniques have not been capable of obtaining such low levels on a repeated, wide-spread consistent basis.
  • the subject invention is able to produce a glass medical container 10 that is substantially free tungsten or derivatives thereof without the need for additional annealing, sterilization or washing steps.
  • the glass blank 24 is an intermediate product that is both unsterilized and unwashed.
  • the glass medical container 10 may be subjected to annealing, sterilizing and air or liquid washing, although such further processing is not always carried out (such unsterilized containers being referred to as “bulk” processed containers).
  • the sterilizing and washing steps may provide for additional removal of any residual tungsten or derivatives thereof which may be present.
  • This residual tungsten or derivatives thereof may have come from the glass raw material, tooling which contacts the glass during formation, or tungsten pins used in the process.
  • the aforementioned levels of tungsten or derivatives thereof, however, are achieved in accordance with the present invention without the additional annealing, sterilizing or washing processes.
  • Levels of tungsten or derivatives thereof may be measured by any technique. Different techniques may provide different results depending on how aggressively the tungsten or derivatives thereof is removed from the glass medical container for testing (i.e., more aggressive techniques remove higher levels of tungsten residue). With reference to Wang, et al., Journal of Pharmaceutical and Biomedical Analysis, 19 (1999) 937-943, “Determination of Tungsten in Bulk Drug Substance and Intermediates by ICP-AES and ICP-MS”, a method of measuring levels of tungsten in drugs is described. Similar methodology can be used for measuring tungsten-containing residue levels. The inventors herein relied on the following procedure to measure the aforementioned levels of tungsten or derivatives thereof:
  • the aforementioned levels of tungsten or derivatives thereof are actually measured concentration levels of tungsten in the extracted solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Containers Having Bodies Formed In One Piece (AREA)
  • Re-Forming, After-Treatment, Cutting And Transporting Of Glass Products (AREA)
US11/664,236 2004-09-30 2005-09-30 Method For Reducing Or Eliminating Residue In A Glass Container And A Glass Container Made In Accordance Therewith Abandoned US20080103438A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/664,236 US20080103438A1 (en) 2004-09-30 2005-09-30 Method For Reducing Or Eliminating Residue In A Glass Container And A Glass Container Made In Accordance Therewith
US17/326,022 US20210269349A1 (en) 2004-09-30 2021-05-20 Method For Reducing or Eliminating Residue in a Glass Container and a Glass Container made in Accordance Therewith

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61491404P 2004-09-30 2004-09-30
PCT/US2005/035710 WO2006039705A2 (fr) 2004-09-30 2005-09-30 Procede permettant de reduire ou d'eliminer des residus dans un contenant en verre et contenant en verre ainsi obtenu
US11/664,236 US20080103438A1 (en) 2004-09-30 2005-09-30 Method For Reducing Or Eliminating Residue In A Glass Container And A Glass Container Made In Accordance Therewith

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/035710 A-371-Of-International WO2006039705A2 (fr) 2004-09-30 2005-09-30 Procede permettant de reduire ou d'eliminer des residus dans un contenant en verre et contenant en verre ainsi obtenu

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/853,276 Continuation US9994477B2 (en) 2004-09-30 2015-09-14 Method for reducing or eliminating residue in a glass container and a glass container made in accordance therewith

Publications (1)

Publication Number Publication Date
US20080103438A1 true US20080103438A1 (en) 2008-05-01

Family

ID=36072208

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/664,236 Abandoned US20080103438A1 (en) 2004-09-30 2005-09-30 Method For Reducing Or Eliminating Residue In A Glass Container And A Glass Container Made In Accordance Therewith
US14/853,276 Expired - Lifetime US9994477B2 (en) 2004-09-30 2015-09-14 Method for reducing or eliminating residue in a glass container and a glass container made in accordance therewith
US15/979,797 Expired - Lifetime US11040905B2 (en) 2004-09-30 2018-05-15 Method for reducing or eliminating residue in a glass container and a glass container made in accordance therewith
US17/326,022 Abandoned US20210269349A1 (en) 2004-09-30 2021-05-20 Method For Reducing or Eliminating Residue in a Glass Container and a Glass Container made in Accordance Therewith

Family Applications After (3)

Application Number Title Priority Date Filing Date
US14/853,276 Expired - Lifetime US9994477B2 (en) 2004-09-30 2015-09-14 Method for reducing or eliminating residue in a glass container and a glass container made in accordance therewith
US15/979,797 Expired - Lifetime US11040905B2 (en) 2004-09-30 2018-05-15 Method for reducing or eliminating residue in a glass container and a glass container made in accordance therewith
US17/326,022 Abandoned US20210269349A1 (en) 2004-09-30 2021-05-20 Method For Reducing or Eliminating Residue in a Glass Container and a Glass Container made in Accordance Therewith

Country Status (6)

Country Link
US (4) US20080103438A1 (fr)
EP (1) EP1809579B1 (fr)
JP (1) JP5238255B2 (fr)
CN (1) CN101061073A (fr)
ES (1) ES2392645T3 (fr)
WO (1) WO2006039705A2 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080064743A1 (en) * 2006-09-08 2008-03-13 Wyeth Dry powder compound formulations and uses thereof
US20080188823A1 (en) * 2005-01-12 2008-08-07 Biogen Idec Ma Inc Method for Delivering Interferon-Beta
US8003794B2 (en) 2005-05-25 2011-08-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
WO2012085619A1 (fr) 2010-12-20 2012-06-28 Becton Dickinson France Outil pour la formation de récipients en verre à usage médical exempts de contamination par un élément étranger
US8247425B2 (en) 2008-09-30 2012-08-21 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8343992B2 (en) 2005-05-25 2013-01-01 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US8552025B2 (en) 2003-04-08 2013-10-08 Progenics Pharmaceuticals, Inc. Stable methylnaltrexone preparation
US9102680B2 (en) 2007-03-29 2015-08-11 Wyeth Llc Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US9314461B2 (en) 2010-03-11 2016-04-19 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US12303592B2 (en) 2006-08-04 2025-05-20 Wyeth, Llc Formulations for parenteral delivery of compounds and uses thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012101948A1 (de) * 2012-03-08 2013-09-12 Schott Ag Formwerkzeug, Verfahren und Vorrichtung zur lasergestützten Glasformung
DE102015111993A1 (de) 2015-07-23 2017-01-26 Schott Ag Formdorn mit Diffusionsschicht zur Glasformung
DE102015117215B4 (de) * 2015-10-08 2019-03-14 Gerresheimer Bünde Gmbh Vorrichtung und Verfahren zur Herstellung eines medizinischen Glasbehälters
DE102015117422A1 (de) 2015-10-13 2017-04-13 Schott Ag Wolfram-haltiger Formdorn zur Glasformung
DE102016122061A1 (de) * 2016-11-16 2018-05-17 Schott Ag Verfahren zur Herstellung von Glasfläschchen mit geringer Delaminationsneigung unter der Einwirkung einer Spülgasströmung
IT202000014869A1 (it) * 2020-06-22 2021-12-22 Nuova Ompi Srl Apparato di formatura del cono di alloggiamento di un ago in una siringa, metodo di realizzazione del cono di alloggiamento di un ago in una siringa e relativa siringa

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1999525A (en) * 1933-06-02 1935-04-30 Corning Glass Works Shaping glass
US2090861A (en) * 1936-05-14 1937-08-24 Eisele Logan Method of making a hypodermic syringe
US2190296A (en) * 1938-08-27 1940-02-13 Westinghouse Electric & Mfg Co Guide for molten material
US2306995A (en) * 1939-06-02 1942-12-29 Palmer Company Method of making capillary tubes and the like
US2368170A (en) * 1942-05-07 1945-01-30 Macgregor Instr Company Machine for fabricating glass
US2583431A (en) * 1942-02-18 1952-01-22 Westinghouse Electric Corp Manufacture of glass tubing and cane
US4388094A (en) * 1981-12-21 1983-06-14 Corning Glass Works Method and apparatus for producing tubular glass article
US4541474A (en) * 1979-12-21 1985-09-17 Castolin S.A. Process for manufacturing a moulding plunger for hollow glass objects
US5312577A (en) * 1992-05-08 1994-05-17 Bioject Inc. Method for manufacturing an ampule
US20010037660A1 (en) * 1998-11-19 2001-11-08 Jose-De-Jesus Delgado-Carranza Method and machine for the manufacturing of syringes
US20020078713A1 (en) * 2000-11-30 2002-06-27 Ngk Insulators, Ltd. Glass-forming mold and a manufacturing method thereof
US6415631B1 (en) * 1996-09-25 2002-07-09 Weston Medical Limited Method and apparatus for making an article from a formable material

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2188636A (en) * 1938-08-24 1940-01-30 Owens Illinois Glass Co Platinum alloy for contacting molten glass
GB526688A (en) 1939-03-22 1940-09-24 Samuel James Everett Improvements relating to the manufacture of glass barrels for syringes and of like tubular articles
GB600667A (en) 1941-12-10 1948-04-15 Macgregor Instr Company Improvements in and relating to glass fabrication
US2705275A (en) * 1954-03-17 1955-03-29 Westin Axel Dies for necking tube ends
US2869286A (en) * 1955-10-28 1959-01-20 Jack G Lubelle Apparatus for forming tubular structures in glassware
DE1224002B (de) 1961-07-31 1966-09-01 Owens Jllinois Inc Drehbarer Dorn zur Herstellung von zylindrischen Rohren und Staeben aus Glas
US3723081A (en) * 1971-11-26 1973-03-27 Airco Inc Break seal
US3973717A (en) * 1975-04-21 1976-08-10 Ppg Industries, Inc. Bushing fabrication
US4118237A (en) * 1977-08-04 1978-10-03 Corning Glass Works Glass-ceramics displaying inherent lubricity
GB8334373D0 (en) 1983-12-23 1984-02-01 Gen Electric Co Plc Dc-dc converter
DE69113291T3 (de) * 1990-02-20 1999-08-26 Ishizuka Glass Verfahren und Vorrichtung zum Herstellen von Glascontainern.
JPH0676233B2 (ja) * 1990-05-30 1994-09-28 日本硝子産業株式会社 ガラスアンプルまたは管瓶、及びその製造方法
DE4028823C2 (de) * 1990-09-11 1994-07-07 Schott Glaswerke Vorrichtung und Formfinger zum Formen eines Mündungsbereiches an einem Glasfläschchen
DE4326143A1 (de) 1993-08-04 1993-12-09 Diether Boettger Stirrer- und Plungergeräte für geschmolzenes Glas
DE4440702C2 (de) 1994-11-15 1997-04-30 Ilmenau Tech Glas Drehplunger für Glasauslauföffnungen
DE19609199A1 (de) * 1996-03-09 1997-09-11 Vetter & Co Apotheker Verfahren zur Bearbeitung von Werkstücken aus festen Materialien sowie Vorrichtung zur Durchführung des Verfahrens
DE19644673A1 (de) 1996-10-27 1998-04-30 Diether Boettger Rotationsgeräte aus Edel- und/oder Nichtedelmetall
DE19713311C2 (de) 1997-03-29 1999-03-11 Schott Glas Verfahren und Vorrichtung zur Erzeugung von großflächigen Präzisionsstrukturen auf Flachglas
JPH11322350A (ja) 1998-05-08 1999-11-24 Nippon Electric Glass Co Ltd ガラス管製造用スリーブ
DE19847549C1 (de) 1998-10-15 2000-06-15 Schott Glas Formgebungswerkzeug mit strukturierter Oberfläche zum Erzeugen von Strukturen auf Glas und seine Anwendung bei der Struktierung von Kanalplatten
AU2357501A (en) 1999-11-17 2001-05-30 Carl-Zeiss-Stiftung Trading As Schott Glaswerke Method for microstructuring the form-giving surface of a form-giving tool for producing microstructures in glass or synthetic material and form-giving tool appurtenant thereto
DE10108958A1 (de) * 2001-02-19 2002-09-12 Arzneimittelgesellschaft Mit B Vorrichtung und Verfahren zur Fertigstellung einer Spritze für medizinische Zwecke
US20030046956A1 (en) * 2001-08-30 2003-03-13 Anderson James G. Method and apparatus for crucible forming
US20040129030A1 (en) * 2002-01-17 2004-07-08 Haruyoshi Tanada Method and device for manufacturing glass tube
KR20040078640A (ko) * 2002-01-30 2004-09-10 스미토모 덴키 고교 가부시키가이샤 유리관의 제조 방법 및 제조 장치
JP2003238172A (ja) * 2002-02-14 2003-08-27 Fuji Electric Co Ltd ガラス成形用金型および該金型を用いたガラス成形法
US20050252244A1 (en) * 2003-04-09 2005-11-17 Fred Heldoorn Method, system and apparatus for a takeout holder and insert
DE102004037491B4 (de) * 2004-07-26 2008-02-28 Schott Ag Vorrichtung und Verfahren zum Vorspannen von länglichen, hohlen Gegenständen aus Glas und Verwendung der Vorrichtung
JP6049710B2 (ja) 2011-07-01 2016-12-21 トゥルーカー インコーポレイテッド 利用可能販売店の選択、フィルタリング、および／または提示のための方法およびシステム

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1999525A (en) * 1933-06-02 1935-04-30 Corning Glass Works Shaping glass
US2090861A (en) * 1936-05-14 1937-08-24 Eisele Logan Method of making a hypodermic syringe
US2190296A (en) * 1938-08-27 1940-02-13 Westinghouse Electric & Mfg Co Guide for molten material
US2306995A (en) * 1939-06-02 1942-12-29 Palmer Company Method of making capillary tubes and the like
US2583431A (en) * 1942-02-18 1952-01-22 Westinghouse Electric Corp Manufacture of glass tubing and cane
US2368170A (en) * 1942-05-07 1945-01-30 Macgregor Instr Company Machine for fabricating glass
US4541474A (en) * 1979-12-21 1985-09-17 Castolin S.A. Process for manufacturing a moulding plunger for hollow glass objects
US4388094A (en) * 1981-12-21 1983-06-14 Corning Glass Works Method and apparatus for producing tubular glass article
US5312577A (en) * 1992-05-08 1994-05-17 Bioject Inc. Method for manufacturing an ampule
US6415631B1 (en) * 1996-09-25 2002-07-09 Weston Medical Limited Method and apparatus for making an article from a formable material
US20010037660A1 (en) * 1998-11-19 2001-11-08 Jose-De-Jesus Delgado-Carranza Method and machine for the manufacturing of syringes
US6341502B2 (en) * 1998-11-19 2002-01-29 Ampolletas, S.A. De C.V. Method and machine for the manufacturing of syringes
US20020078713A1 (en) * 2000-11-30 2002-06-27 Ngk Insulators, Ltd. Glass-forming mold and a manufacturing method thereof

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552025B2 (en) 2003-04-08 2013-10-08 Progenics Pharmaceuticals, Inc. Stable methylnaltrexone preparation
US10376584B2 (en) 2003-04-08 2019-08-13 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US9669096B2 (en) 2003-04-08 2017-06-06 Progenics Pharmaceuticals, Inc. Stable pharmaceutical formulations of methylnaltrexone
US10220074B2 (en) 2005-01-12 2019-03-05 Biogen Ma Inc. Method for delivering interferon-beta
US20080188823A1 (en) * 2005-01-12 2008-08-07 Biogen Idec Ma Inc Method for Delivering Interferon-Beta
AU2006204937B2 (en) * 2005-01-12 2011-02-10 Biogen Ma Inc. Method for delivering Interferon-beta
US9452106B2 (en) 2005-01-12 2016-09-27 Biogen Ma Inc Method for delivering interferon-β
US8784399B2 (en) * 2005-01-12 2014-07-22 Biogen Idec Ma Inc. Method for delivering interferon-β
US9597327B2 (en) 2005-05-25 2017-03-21 Progenics Pharmaceuticals, Inc. Synthesis of (R)-N-methylnaltrexone
US8343992B2 (en) 2005-05-25 2013-01-01 Progenics Pharmaceuticals, Inc. Synthesis of R-N-methylnaltrexone
US8916581B2 (en) 2005-05-25 2014-12-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US8003794B2 (en) 2005-05-25 2011-08-23 Progenics Pharmaceuticals, Inc. (S)-N-methylnaltrexone
US12303592B2 (en) 2006-08-04 2025-05-20 Wyeth, Llc Formulations for parenteral delivery of compounds and uses thereof
US20080064743A1 (en) * 2006-09-08 2008-03-13 Wyeth Dry powder compound formulations and uses thereof
US9879024B2 (en) 2007-03-29 2018-01-30 Progenics Pharmaceuticals., Inc. Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US8772310B2 (en) 2007-03-29 2014-07-08 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8853232B2 (en) 2007-03-29 2014-10-07 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US9102680B2 (en) 2007-03-29 2015-08-11 Wyeth Llc Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof
US8338446B2 (en) 2007-03-29 2012-12-25 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
US8916706B2 (en) 2008-02-06 2014-12-23 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8471022B2 (en) 2008-02-06 2013-06-25 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone
US8455644B2 (en) 2008-09-30 2013-06-04 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8420663B2 (en) 2008-09-30 2013-04-16 Wyeth Peripheral opioid receptor antagonists and uses thereof
US9492445B2 (en) 2008-09-30 2016-11-15 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US9180125B2 (en) 2008-09-30 2015-11-10 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
KR101566675B1 (ko) 2008-09-30 2015-11-09 와이어쓰 엘엘씨 말초 오피오이드 수용체 길항제 및 이의 용도
US9724343B2 (en) 2008-09-30 2017-08-08 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US8822490B2 (en) 2008-09-30 2014-09-02 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
EP3608322A1 (fr) 2008-09-30 2020-02-12 Wyeth LLC Syringue contenant la nmtx bromide
US8247425B2 (en) 2008-09-30 2012-08-21 Wyeth Peripheral opioid receptor antagonists and uses thereof
US10376505B2 (en) 2010-03-11 2019-08-13 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US10307417B2 (en) 2010-03-11 2019-06-04 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US10507206B2 (en) 2010-03-11 2019-12-17 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
US9314461B2 (en) 2010-03-11 2016-04-19 Wyeth, Llc Oral formulations and lipophilic salts of methylnaltrexone
WO2012085619A1 (fr) 2010-12-20 2012-06-28 Becton Dickinson France Outil pour la formation de récipients en verre à usage médical exempts de contamination par un élément étranger

Also Published As

Publication number Publication date
US9994477B2 (en) 2018-06-12
US20180257972A1 (en) 2018-09-13
EP1809579B1 (fr) 2012-08-08
WO2006039705A2 (fr) 2006-04-13
ES2392645T3 (es) 2012-12-12
JP5238255B2 (ja) 2013-07-17
US20160002087A1 (en) 2016-01-07
CN101061073A (zh) 2007-10-24
US20210269349A1 (en) 2021-09-02
EP1809579A2 (fr) 2007-07-25
US11040905B2 (en) 2021-06-22
JP2008520522A (ja) 2008-06-19
WO2006039705A3 (fr) 2006-06-01

Similar Documents

Publication Publication Date Title
US11040905B2 (en) Method for reducing or eliminating residue in a glass container and a glass container made in accordance therewith
CN105745030B (zh) 处理液体药物制剂的方法
JP4351056B2 (ja) 無針注射器薬剤カプセル及びその充填方法
US10981822B2 (en) Device and method for producing a medical glass container
JP2008520522A5 (fr)
WO2009152562A1 (fr) Procédé de fabrication d'une microcavité dans un solide
JP7496680B2 (ja) ガラス製容器およびガラス製容器を製造する方法
KR101217373B1 (ko) 생식 물질을 분리하여 크리요탱크 내에 보관하기 위한 장치 및 방법
US11008243B2 (en) Method for producing a syringe having a piercing means
JP7756114B2 (ja) シリンジに針を収容するためのコーンを成形する装置、シリンジに針を収容するためのコーンを作る方法、及び、これらに関するシリンジ
US10098812B2 (en) Multi-component container
DE10128460A1 (de) Vorrichtung und Verfahren zum Sammeln von kleinen wässrigen Flüssigkeitsproben
EP2094337A2 (fr) Stérilisation gazeuse de contenants imperméables par l'utilisation de matière poreuse
NL2009945C2 (en) Process and device for minimally invasive deep tissue probing.
CN112295064A (zh) 具有封闭端容器的容器组件和封闭端容器
JP2023130356A (ja) 薬液用容器及びこの型の容器の充填方法
JP2015035957A (ja) 滅菌確認用工程試験用具
JP2002210009A (ja) 肉厚な開口端部を有する医療用注入器具およびその成形方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: BECTON, DICKINSON AND COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRAIS, ALFRED W.;CORTES, ARTURO;DELABIE, PATRICE;AND OTHERS;SIGNING DATES FROM 20070327 TO 20071213;REEL/FRAME:028357/0469

AS Assignment

Owner name: BECTON, DICKINSON AND COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WALES, EDOUARD;REEL/FRAME:028408/0160

Effective date: 20120620

AS Assignment

Owner name: BECTON, DICKINSON AND COMPANY, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COCHETEUX, BRUNO;REEL/FRAME:028543/0026

Effective date: 20120712

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION